Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Wearing apparel – fabric – or cloth
Reexamination Certificate
2000-05-25
2002-12-31
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Wearing apparel, fabric, or cloth
C424S443000, C424S401000, C424S400000, C604S350000
Reexamination Certificate
active
06500443
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to the use of a treatment composition to enhance skin health. The treatment composition includes a surfactant and a sacrificial substrate that can be applied to a sheet material such as a nonwoven web, such that the composition will impart adequate fluid handling properties to the sheet material and will subsequently be transferred to the skin. The treatment composition may further be used as a vehicle to deliver active agents to the skin.
BACKGROUND OF THE INVENTION
The skin is naturally an excellent barrier to the penetration of many foreign substances. From time-to-time, the natural ability of the skin to protect is compromised by external factors including abrasions, irritants and the like. Attempts have been made in recent years to promote skin health through the use of creams, lotions and fiber products containing additives in order to maintain the skin health. Effective delivery of compositions via fiber products that can enhance or prevent damage to the underlying protective barrier of skin is not yet known.
Enhancing skin health has many advantages including: 1) protecting the skin and maintaining the skin in a moist state, essentially free from chapping or irritation, 2) pH buffering and barrier enhancement to maintain or enhance such base properties of skin, 3) inhibition of irritants that are suspected to promote irritant or allergic contact dermatitis, and 4) maintaining the lubricity of skin.
The permeability of the skin to a foreign substance is influenced by a combination of physico-chemical parameters for both the object and the vehicle, if applicable, that delivers the object. Maintaining health of the skin and its underlying barrier properties requires optimal physico-chemical properties of the skin.
When skin is attacked by proteases, the stratum corneum layer of the skin is compromised and the skin subsequently becomes inflamed. There are currently several known lotions and creams available that treat inflammation once it has occurred. To the user, however, discomfort has already been transpired because of the inflammation. A need still exists for a method and combination of preventing skin irritation rather than treating it.
There is a need for a treatment combination for use with a sheet material that is capable of delivering a thin, tenacious, substantially continuous film of the sacrificial substrate to the skin that can prevent or reduce skin irritation, maintain pH, and maintain skin hydration and lubrication. The combination of the instant invention fulfills this need. Additionally, while skin wellness additives are known, other compositions have had the undesired side effect of reducing wettability, or the fluid intake rate, of the sheet material. There remains a need for a treatment composition for application and use with a sheet material that will not adversely affect fluid properties of the sheet material, e.g. fast and sustainable fluid intake rate.
SUMMARY OF THE INVENTION
The present invention relates to a topical delivery system effective in depositing a thin, tenacious and substantially continuous coating of a sacrificial substrate, e.g. protein or protein hydrolysate, on skin by an aqueous emulsion mediated dissolution of the sacrificial substrate from a sheet material with subsequent transfer and deposition onto the skin. Coatings of the sacrificial substrate on skin resist removal, thereby providing a protective barrier against chemically- and biochemically-induced skin damage. The treatment combination also provides a vehicle for administering an effective dose of a active agent to the skin surface.
REFERENCES:
patent: 3061512 (1962-10-01), Anderson, Jr. et al.
patent: 3991184 (1976-11-01), Kludas et al.
patent: 4233212 (1980-11-01), Otoi et al.
patent: 4344967 (1982-08-01), Easton et al.
patent: 4454159 (1984-06-01), Musher
patent: 4463017 (1984-07-01), Hidalgo et al.
patent: 4556560 (1985-12-01), Buckingham
patent: 4784986 (1988-11-01), Usher
patent: 4839165 (1989-06-01), Hoppe et al.
patent: 4839168 (1989-06-01), Abe et al.
patent: 4906460 (1990-03-01), Kim et al.
patent: 4973473 (1990-11-01), Schneider et al.
patent: 5009813 (1991-04-01), Watanabe et al.
patent: 5069898 (1991-12-01), Goldberg
patent: 5091193 (1992-02-01), Enjolras et al.
patent: 5306444 (1994-04-01), Kitamura et al.
patent: 5385696 (1995-01-01), Repinec, Jr. et al.
patent: 5415813 (1995-05-01), Misselyn et al.
patent: 5494744 (1996-02-01), Everhart et al.
patent: 5519060 (1996-05-01), Sprengeler et al.
patent: 5552020 (1996-09-01), Smith et al.
patent: 5609587 (1997-03-01), Roe
patent: 5624675 (1997-04-01), Kelly
patent: 5637616 (1997-06-01), Sharpe et al.
patent: 5641483 (1997-06-01), Beaulieu
patent: 5648389 (1997-07-01), Gans et al.
patent: 5676967 (1997-10-01), Williams et al.
patent: 5693515 (1997-12-01), Clark et al.
patent: 5698184 (1997-12-01), Pickart
patent: 5728461 (1998-03-01), Nogata et al.
patent: 5795573 (1998-08-01), Paradise
patent: 5830481 (1998-11-01), Cauwet-Martin et al.
patent: 6028016 (2000-02-01), Yahiaoui et al.
patent: 199 03 717 (2000-08-01), None
patent: 0 750 903 (1997-01-01), None
patent: 0761867 (1997-03-01), None
patent: 0763620 (1997-03-01), None
patent: 0761867 (1998-02-01), None
patent: 0841065 (1998-05-01), None
patent: 0 842 606 (1998-05-01), None
patent: 0 875 233 (1998-11-01), None
patent: 2242198 (1991-09-01), None
patent: 11-50397 (1999-02-01), None
patent: 84/02845 (1984-08-01), None
patent: 91/02538 (1991-03-01), None
patent: 95/13806 (1995-05-01), None
patent: 96/03149 (1996-02-01), None
patent: 96/16681 (1996-06-01), None
patent: 98/10134 (1998-03-01), None
patent: 99/12504 (1999-03-01), None
patent: 99/12583 (1999-03-01), None
patent: 99/32706 (1999-07-01), None
Remington: The Science and Practice of Pharmacy. 19thed. Gennaro AR, editor. Easton PA: Mack Publishing Co; 1995, chapter 67, pp. 1248-1267.
Manda, F. et al., “Skin lesions due to okra (Hibiscus esculentusL.): proteolytic activity and allergenicity of okra”Contact Dermatitis1992 Feb;26(2):95-100.
Andersen, P.H. et al., “Faecal enzymes:in vivo human skin irritation”Contact Dermatitis1994 Mar;30(3):152-158.
Buckingham, K.W. et al., “Etiologic factors in diaper dermatitis: the role of feces”Pediatric Dermatology1986 Feb;3(2):107-112.
Franzke, C.W. et al., “Antileukoprotease inhibits stratum corneum chymotryptic enzyme. Evidence for a regulative function in desquamation”J Biol Chem1996 Sep 6;271(36):1886-90.
Katz, B.A. et al., “Design of potent selective zinc-mediated serine protease inhibitors.”Nature1998 Feb 5;391(6667):608-12.
Croda, Inc., Personal Care, CROSILKQUAT, “INCI Name: Cocodimonium Hydroxypropyl Silk Amino Acids”, DS-14R-1, Jul. 6, 1994, p. 1-6.
Croda, Inc., Crodata: “CROSILK Liquid-Silk Amino Acids”, p. 1-4.
Croda, Inc., Crodata:“CROSILK POWDER”, p. 1-5.
Croda, Inc., Crodata: “CROSILK 10,000(Hydrolyzed Silk)”, p. 1-4.
Croda, Inc., Personal Care, CRODACOL Series, “INCI Names: CRODACOL C-70 Cetyl Alcohol; CRODACOL C-95 NF Cetyl Alcohol; CRODACOL S-70 Stearyl Alcohol; CRODACOL S-95 NF Stearyl Alcohol; CRODACOL CS-50 Cetearyl Alcohol; CRODACOL 1618 Cetearyl Alcohol”, DS-81, May 31, 1995, p. 1-8.
Croda, Inc., Personal Care, CROSULTAINES (Vegetable Derived Hydroxysultaines), “INCI Names: CROSULTAINE C-50 Cocamidopropyl Hydroxysultaine; CROSULTAINE E-30 Erucamidopropyl Hydroxysultaine”, DS-33R-1, Jun. 10, 1994, p. 1-9.
Centerchem, Inc., Certificate of Analysis, “Sericin”, Jun. 21, 1996, 2 pages.
Croda, Inc., Croda Conservation International, CRONATURAL BRAZIL NUT OIL, “INCI Name: Brazil Nut (Bertholletia Excelsa) Oil”, DS-68R-1, Apr. 22, 1994, p. 1-5.
English Abstract for DE 199 03 717 from corresponding WO 00/44343.
English Translation of Abstract for JP 11-350,352 A.
Akin Frank Jerrel
Di Luccio Robert Cosmo
Huard Linda Susan
Otts David Roland
Tyrrell David John
Ghali Isis
Kyriakou Christos S.
Letson William W.
Page Thurman K.
LandOfFree
Delivery of a sacrificial substrate to inhibit protease... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Delivery of a sacrificial substrate to inhibit protease..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Delivery of a sacrificial substrate to inhibit protease... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2989270